Three research compounds dominate searches in the metabolic peptide space — Semaglutide, Tirzepatide, and Retatrutide — and they are constantly compared, often inaccurately. The cleanest way to understand them is by how many receptors each one targets. This guide lays out the difference, strictly in a research context, with no human-use claims.
The one distinction that explains everything: receptor targeting
All three are synthetic peptides in the incretin-agonist class, and they differ mainly in how many pathways they act on:
Semaglutide — single agonist (GLP-1). It acts on the glucagon-like peptide-1 receptor alone. It is the reference single-target compound that established this research class.
Tirzepatide — dual agonist (GIP + GLP-1). It adds the glucose-dependent insulinotropic polypeptide receptor to the GLP-1 target, making it a two-pathway compound.
Retatrutide — triple agonist (GIP + GLP-1 + glucagon). It adds the glucagon receptor on top of the other two, and is an investigational compound — the newest and least-characterized of the three.
That single → dual → triple progression is the through-line of the whole research class, and it is the fact most comparison discussions get muddled. More targets is not automatically “better”; it is simply a different, broader research profile.
What they share
All three are supplied lyophilized, reconstituted the same way, and handled the same way in the lab. The diluent volume sets concentration — our free reconstitution calculator handles the math for any of them, and our reconstitution guide covers technique. All three are research compounds — none is an approved medication in the form sold here, and none should be described in terms of outcomes in people.
What matters more than which one
Whichever compound a research protocol calls for, the variable that actually determines the quality of your results is the same: is the material what the label says, for the exact lot you receive? That comes down to documentation — a current COA from a named independent lab, showing identity and purity, with a lot number matching your vial. Every Summit Research batch of all three is tested eight times across independent laboratories with the COA published for the lot before listing. If reading a COA is new to you, our guide on how to read a peptide COA takes about five minutes.
The short version
Count the receptors: Semaglutide targets one, Tirzepatide two, Retatrutide three. Everything else about how they are handled in a research setting is the same — including the one non-negotiable, which is published, verifiable third-party testing for the lot in front of you.
Browse the Summit Research catalog →
All compounds discussed are sold strictly for laboratory and research use only. They are not for human or veterinary use, and material sold for research is not an approved medication. Nothing in this guide is medical advice or a claim regarding use in humans or animals. Provided for informational and research purposes only.
[…] In published research, dual incretin-receptor agonists such as Tirzepatide are studied for their effects on metabolic pathways, and the compound is frequently used as a reference point for the multi-target approach to incretin research. Material sold here is a research compound, not an approved medication or therapeutic product, and any description of outcomes in people falls outside what a research supplier represents. For how the single-, dual-, and triple-agonist compounds line up, see our GLP-class comparison guide. […]